SGAs are associated with significant weight gain, cardiometabolic side effects, and an increased risk of chronic diseases such as diabetes and heart disease. Children on antipsychotics seem to be at higher risk of early weight gain, irrespective of the applied SGA. Obesity is associated with a state of low-grade chronic inflammation, resulting in dysregulation of immune system responses.
Prof. Louise Gallagher (University of Dublin, Ireland) explained that the aim of the study was to investigate the effect of SGAs on immunophenotype, immune cell responses, and cardiometabolic function in children (5–18 years) longitudinally over 12 months.
The results showed rapid weight gain within 3 months of commencing SGA treatment, especially in children with a lower BMI at baseline. The proinflammatory cytokines TNF-alpha and IL-17 increased within 3 months after commencing SGAs. IL-17 is released from mucosal-associated invariant T cells (MAIT cells) and is associated with insulin resistance. The frequency of MAIT cells also increased on SGAs. The study results confirmed that MAIT cells produce inflammatory cytokines, which are differentially regulated by dopamine. Prof. Gallagher noted that inflammatory MAIT cells are implicated in the development of metabolic disease: a recent study showed that an increase in MAIT cells promoted metabolic dysfunction in a mouse model [2]. The inflammatory changes found in this cohort of SGAs are similar to those found in previous studies on childhood obesity [1].
Prof. Gallagher summarised the importance of this research: “We showed novel mechanisms behind weight gain that occurs with antipsychotic medication. We identified targets in the inflammatory response to antipsychotics, allowing implementation of prevention strategies, such as identifying those most at risk of having a proinflammatory profile, as well as novel targets to potentially reduce these side effects. Our study offers a unique insight into the effect of weight gain on the immune system over time.”
- Gallagher L. Antipsychotics cause the development of an inflammatory phenotype: a 12-month longitudinal study. S.10.02, ECNP 2021 Congress, 2–5 October.
- Toubal A. Nat Commun. 2020;11(1):1–22.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Post-COVID-19 depression responds well to SSRIs Next Article
Alcohol consumption during lockdown »
« Post-COVID-19 depression responds well to SSRIs Next Article
Alcohol consumption during lockdown »
Table of Contents: ECNP 2021
Featured articles
Anxiety and Stress
Anxiolytic activity of a novel orexin-1 receptor antagonist
Autism
Finding biomarkers for improved patient stratification
Behavioural Disorders
Sex similarities and differences in the neurobiology of aggression
Risky driving and lifestyle may have a common psychobiological basis
Cannabidiol for cannabis cessation shows positive results
Somatic comorbidities of ADHD: epidemiological and genetic data
Novel approaches to understanding the social brain
COVID-19
Alcohol consumption during lockdown
Post-COVID-19 depression responds well to SSRIs
Impact of COVID-19 on patients with psychotic disorders
Mood Disorders
Depression and brain structures associations across a lifespan
BDNF/TrkB pathway promising alternative for new antidepressants
Zuranolone reduces symptoms of major depression
Vortioxetine effectively reduces symptoms of depression and anxiety
Esketamine outperforms real-world management for treatment-resistant depression: preliminary results
Smartphone interventions in bipolar disorder: a position paper
Connecting, challenging, and empowering youth through their smartphone
Personality Disorders
Evaluating vafidemstat for the treatment of borderline personality disorder
Deep brain stimulation effective in the treatment of refractory OCD
Psychotic Disorders
Why antipsychotics cause weight gain
Roluperidone improves negative symptoms in schizophrenia
Other
Brain Prize Lecture: Prof. Jes Olesen on migraine
Laxative may improve cognitive performance
Related Articles
November 26, 2021
Brain Prize Lecture: Prof. Jes Olesen on migraine
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com